Loading
A phase 1/2 trial of IOV-3001 in melanoma and uveal melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel is a phase 1/2 interventional study registered as NCT06940739 by Iovance Biotherapeutics, Inc., with 42 participants planned, started 2025-03-11 and due to reach its primary completion in 2032-06. Interventions recorded: IOV-3001.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Iovance Biotherapeutics and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/